# Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)

> **NCT03992872** · PHASE2 · COMPLETED · sponsor: **Bavarian Nordic** · enrollment: 60 (actual)

## Conditions studied

- Chikungunya

## Interventions

- **BIOLOGICAL:** Chikungunya

## Key facts

- **NCT ID:** NCT03992872
- **Lead sponsor:** Bavarian Nordic
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-20
- **Primary completion:** 2021-01-19
- **Final completion:** 2021-01-19
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-10-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03992872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03992872, "Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03992872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*